To that end, the company is developing innovative approaches that target γ-aminobutyric acid type B (GABAB), orexin-1, and dopamine (DA) D3 receptors. Long-term exposure to drugs of abuse causes ...

Idorsia has become the first drugmaker in the EU to claim approval for a drug for chronic insomnia in the dual orexin receptor antagonist class, ahead of rival drugs from Merck & Co and Eisai.

which are developing a drug that preferentially targets just one of the orexin receptors thought to be more relevant to maintaining wakefulness. Their selective orexin 2 receptor antagonist ...

or orexin receptor 2 (OX2R). These receptors regulate sleep and wakefulness, stress responses, and appetite. Drugs like Belsomra block the activity of these neurotransmitters by attaching to the ...

André C. Muller, CEO of Idorsia, commented: “The team at Idorsia has been very successful at generating innovative drugs that can redefine the way diseases are treated. Last year, we received ...